Evidence map›Paper›PMID 31945729›Full record

ArticleMolecular therapy. Nucleic acids2020

circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252.

Shu Zhang, Jie Cheng, Chenlian Quan, Hao Wen, Zheng Feng, Qin Hu, Jun Zhu, Yan Huang, Xiaohua Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 130 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Role of circular RNA as competing endogenous RNA in ovarian cancer (Review).International journal of molecular medicine · 2024
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shu ZhangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Jie ChengDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Chenlian QuanDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Hao WenDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Zheng FengDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Qin HuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Jun ZhuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Yan HuangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Xiaohua WuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China. Electronic address: drwuxh@163.com.
Fudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the malignant tumor of the female reproductive system with the highest fatality rate. Tolerance to chemotherapeutic drugs such as paclitaxel (PTX) occurring in the very early stage is one of the important factors of the poor prognosis of ovarian cancer. Herein, we aim to study the dysregulation of a particular circular RNA (circRNA), circCELSR1 (hsa_circ_0063809), and its role in the progression and PTX resistance of ovarian cancer. The high expression of circCELSR1 in PTX-resistant tissues of ovarian cancer and PTX-resistant ovarian cancer cells (SKOV3/PTX and HeyA-8/PTX) was determined by microarray analyses and quantitative real-time PCR. Cell Counting Kit-8 (CCK-8) assays were performed to investigate the effect of circCELSR1 on PTX sensitivity of ovarian cancer cells. Flow cytometer assays were used to detect cell cycle and apoptosis of ovarian cancer cells. The effect of circCELSR1 on ovarian cancer cells was assessed in vitro and in vivo. The microRNA (miRNA) sponge mechanism of circRNAs was demonstrated using dual-luciferase reporter and RNA immunoprecipitation assays. By microarray (5 PTX-resistant ovarian cancer tissues νs 5 PTX-sensitive ovarian cancer tissues) and qRT-PCR (36 normal ovarian tissues and ovarian cancer tissues) we identified circCELSR1 to be dramatically highly expressed in ovarian cancer samples and correlated with PTX resistance. Compared with sensitive cell lines, circCELSR1 was also highly expressed in PTX-resistant ovarian cancer cell lines, and circCELSR1 silencing enhanced PTX-induced cytotoxicity in ovarian cancer cells. Meanwhile, the inhibition of circCELSR1 also caused ovarian cancer cell G

Indexed as

CELSR1circular RNAgrowth ovarian cancermicroRNAresistance

Identifiers

PMID31945729
PMCPMC6965731
OpenAlexW2995689405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.